[HTML][HTML] Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis
…, JF Bonneville, J Watelet, JP Pruvo… - … England Journal of …, 2006 - Mass Medical Soc
Background Carotid stenting is less invasive than endarterectomy, but it is unclear whether
it is as safe in patients with symptomatic carotid-artery stenosis. Methods We conducted a …
it is as safe in patients with symptomatic carotid-artery stenosis. Methods We conducted a …
Cervical artery dissections
…, C Lucas, M Gobert, G Deklunder, JP Pruvo - European …, 1997 - karger.com
… 108 Wannebroucq J, Petyt L, Cassim F, Ronde-pierre P, Pruvo JP: Dissection de ľartère
carotide interne révélée par une paralysie iso-lée des IX, X et XΓ nerfs crâniens. Rev Im Med …
carotide interne révélée par une paralysie iso-lée des IX, X et XΓ nerfs crâniens. Rev Im Med …
A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging
Differences in grading signal hyperintensities on magnetic resonance imaging may explain
earlier reported conflicting results in studies of normal aging and dementia. We designed a …
earlier reported conflicting results in studies of normal aging and dementia. We designed a …
Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients
…, T Stojkovic, D Ferriby, S Dubucquoi, JP Pruvo… - Medicine, 2004 - journals.lww.com
Neurologic involvement occurs in approximately 20% of patients with primary Sjögren syndrome
(SS). However, the diagnosis of SS with neurologic involvement is sometimes difficult, …
(SS). However, the diagnosis of SS with neurologic involvement is sometimes difficult, …
New OFSEP recommendations for MRI assessment of multiple sclerosis patients: special consideration for gadolinium deposition and frequent acquisitions
…, O Outteryck, N Pyatigorskaya, JP Pruvo… - Journal of …, 2020 - Elsevier
Purpose New multiple sclerosis (MS) disease-modifying therapies (DMTs), which exert
beneficial effects through prevention of relapse, limitation of disability progression, and …
beneficial effects through prevention of relapse, limitation of disability progression, and …
[HTML][HTML] Trial of deferiprone in Parkinson's disease
…, G Kuchcinski, R Lopes, JP Pruvo… - … England Journal of …, 2022 - Mass Medical Soc
Background Iron content is increased in the substantia nigra of persons with Parkinson’s
disease and may contribute to the pathophysiology of the disorder. Early research suggests that …
disease and may contribute to the pathophysiology of the disorder. Early research suggests that …
Cerebral arteriovenous malformations in children: report on 62 cases
JP Hladky, JP Lejeune, S Blond, JP Pruvo… - Child's Nervous …, 1994 - Springer
A series of 62 children with cerebral arteriovenous malformations admitted to our department
in the course of 17 years (1975–1992) was reviewed in a retrospective study. In 54 cases …
in the course of 17 years (1975–1992) was reviewed in a retrospective study. In 54 cases …
Prevalence and significance of hyperdense middle cerebral artery in acute stroke.
D Leys, JP Pruvo, O Godefroy, PH Rondepierre… - Stroke, 1992 - Am Heart Assoc
Early noncontrast computed tomographic scans may visualize a hyperdense middle
cerebral artery before the infarct becomes visible. This sign disappears within a few days, …
cerebral artery before the infarct becomes visible. This sign disappears within a few days, …
Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
…, D Guerouaou, B Vandenhaute, JP Pruvo… - Acta …, 1995 - Springer
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL) is characterized by a cerebral non-atherosclerotic, non-amyloid angiopathy …
(CADASIL) is characterized by a cerebral non-atherosclerotic, non-amyloid angiopathy …
Early predictors of death and disability after acute cerebral ischemic event
…, C Lucas, P Rondepierre, A Duhamel, JP Pruvo - Stroke, 1995 - Am Heart Assoc
Background and Purpose Many clinical trials are currently being conducted to evaluate the
ability of neuroprotectors and thrombolytic agents to improve survival and functional outcome …
ability of neuroprotectors and thrombolytic agents to improve survival and functional outcome …